Why Scott Gottlieb is the one Trump official everybody seems to like
From the article:
A major sticking point at his confirmation was what Sen. Patty Murray (D-WA) called “unprecedented financial entanglements” — including previous posts on five pharmaceutical company boards.
“Gottlieb is committed to improv[ing] competition in generic drugs, making it easier for generics and biosimilars to come to market,” said Rachel Sachs, a law professor at Washington University in St. Louis, earlier this year. The White House, meanwhile, has done “absolutely nothing on this issue.”
Read the full article here!health care finance health law policy pharmaceuticals rachel sachs